摘要
通过对1例肾功能不全的非瓣膜性房颤患者达比加群酯给药方案的分析,结合国内外相关临床使用指南和治疗进展,总结、分析影响达比加群酯抗凝效果的相关因素,并根据实验室监测评估个体化治疗的安全性及有效性。
Through analysis of dabigatran etexilone dosing regimen in a patient of non-valvular atrial fibrillation with renal insufficiency,according to the latest guidelines and treatment progress,summarized and analyzed the relevant factors affecting the anticoagulant effect of dabigatran etexilate and the laboratory monitoring to assess the safety and efficacy of individualized treatment strategies.
作者
祁蕙
张伟霞
Qi Hui;Zhang Weixia(Department of Pharmacy,Chengdu Sixth People's Hospital,Chengdu 610051,China;Department of Pharmacy,Ruijin Hospital,Shanghai Jiaotong University School of Medicine)
出处
《药物流行病学杂志》
CAS
2020年第11期772-775,共4页
Chinese Journal of Pharmacoepidemiology
关键词
达比加群酯
肾功能不全
P-糖蛋白
活化部分凝血活酶时间
药学监护
Dabigatran etexilate
Renal insufficiency
P-glycoprotein
Activated partial thromboplastin time
Pharmaceutical care
